Similar articles

• A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients.

  Fischer L, Sterneck M, Gahlemann CG, Malago M, Rogiers X, Broelsch CE. Fischer L, et al. Transplant Proc. 2000 Nov;32(7):2125-7. doi: 10.1016/s0041-1345(00)01599-2. Transplant Proc. 2000. PMID: 11120098 Clinical Trial. No abstract available.
• FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation.

  Platz KP, Mueller AR, Neuhaus R, Keck HH, Lobeck H, Neuhaus P. Platz KP, et al. Transplant Proc. 1997 Nov;29(7):2872-4. doi: 10.1016/s0041-1345(97)00714-8. Transplant Proc. 1997. PMID: 9365598 No abstract available.
• Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial.

  Langrehr JM, Klupp J, Junge G, Jonas S, Neuhaus R, Bechstein WO, Neuhaus P. Langrehr JM, et al. Transplant Proc. 2001 May;33(3):2330-1. doi: 10.1016/s0041-1345(01)02011-5. Transplant Proc. 2001. PMID: 11377549 Clinical Trial. No abstract available.
• Neoral is superior to FK 506 in liver transplantation.

  Levy GA. Levy GA. Transplant Proc. 1998 Aug;30(5):1812-5. doi: 10.1016/s0041-1345(98)00442-4. Transplant Proc. 1998. PMID: 9723293 Review. No abstract available.
• Mycophenolate mofetil, tacrolimus, Neoral: from clinical trials to the clinic.

  Pirsch JD. Pirsch JD. Transplant Proc. 1998 Aug;30(5):2223-5. doi: 10.1016/s0041-1345(98)00597-1. Transplant Proc. 1998. PMID: 9723448 Review. No abstract available.